TScan Therapeutics (TCRX) Depreciation & Amortization (CF) (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $693000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 2.21% year-over-year to $693000.0 in Q1 2026; TTM through Mar 2026 was $2.9 million, a 18.43% decrease from a year earlier, with the FY2025 full-year figure at $2.9 million, down 29.27% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $693000.0, down from $723000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for TCRX reached as high as $1.5 million in Q1 2023 and fell as low as $678000.0 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• Across the five-year window, Depreciation & Amortization (CF) surged 154.8% in 2022 and tumbled 45.93% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2022, then declined by 13.75% to $1.3 million in 2023, then sank by 44.45% to $711000.0 in 2024, then climbed by 1.69% to $723000.0 in 2025, then dropped by 4.15% to $693000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $693000.0 in Q1 2026, $723000.0 in Q4 2025, and $767000.0 in Q3 2025.